Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celera, Applied Biosystems go separate ways

This article was originally published in Clinica

Executive Summary

Diagnostic tests and services provider Celera has officially become an independent company, after its separation from parent company Applera was completed Tuesday (July 1). Celera was founded by Applera in 1998 with the mission of sequencing the human genome – since then, its business has grown significantly in the genetic diagnostics and personalised disease management field, particularly through the recent acquisitions of Berkeley HeartLab and Atria Genetics. Celera is now trading under the symbol "CRA". As a result of the separation, Applera has taken on the name of its remaining life science equipment business, Applied Biosystems. In June, the latter agreed to a merger with Invitrogen, in a deal worth $6.9bn (see Clinica No 1311, p 2).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel